| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2022: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2021: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2020: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2018: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Outline of Final Research Achievements |
In this research, we aim to develop a minimally invasive thermal treatment technology to improve the quality of life (QOL) of patients with end-stage respiratory cancer. In this application, we have developed a 'wireless temperature measurement technology' that uses 'Low Curie Point Ferromagnetic Particles (FILCT)' injected into the tumor as a probe for temperature measurement, and a 'wireless temperature measurement and heating device' for hyperthermia that selectively heats only the tumor to a constant temperature of 45°C from the body surface with a high-frequency magnetic field. Furthermore, envisioning clinical application, we have improved the heating efficiency by doubling the frequency of the applied magnetic field, and implemented a 'magnetic flux application detection unit' that integrates the magnetic field application coil and the detection coil, among other things, we have developed various elemental technologies and made the challenges of this method evident.
|
